RESUMO
BACKGROUND: Treatment and control of schistosomiasis, one of the most insidious and serious parasitic diseases, depend almost entirely on a single drug, praziquantel. Since the funding for drug development for poverty-associated diseases is very limited, drug repurposing is a promising strategy. In this study, 73 nonsteroidal anti-inflammatory drugs (NSAIDs) commonly used in medical and veterinary fields were evaluated for their anti-schistosomal properties. METHODS: The efficacy of NSAIDs was first tested against adult Schistosoma mansoni ex vivo using phenotypic screening strategy, effective drugs were further tested in a murine model of schistosomiasis. The disease parameters measured were worm and egg burden, hepato- and splenomegaly. FINDINGS: From 73 NSAIDs, five (mefenamic acid, tolfenamic acid, meclofenamic acid, celecoxib, and diclofenac) were identified to effectively kill schistosomes. These results were further supported by scanning electron microscopy analysis. In addition, the octanol-water partition coefficient, both for neutral and ionized species, revealed to be a critical property for the ex vivo activity profile. Compounds were then tested in vivo using both patent and a prepatent S. mansoni infection in a mouse model. The most effective NSAID was mefenamic acid, which highly reduced worm burden, egg production, and hepato- and splenomegaly. INTERPRETATION: The treatment regimen used in this study is within the range for which mefenamic acid has been used in clinical practice, thus, it is demonstrated the capacity of mefenamic acid to act as a potent anti-schistosomal agent suitable for clinical repurposing in the treatment of schistosomiasis.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Ácido Mefenâmico/farmacologia , Testes de Sensibilidade Parasitária , Schistosoma/efeitos dos fármacos , Esquistossomicidas/farmacologia , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Reposicionamento de Medicamentos , Feminino , Humanos , Ácido Mefenâmico/administração & dosagem , Camundongos , Testes de Sensibilidade Parasitária/métodos , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose/tratamento farmacológico , Esquistossomose/parasitologia , Esquistossomicidas/administração & dosagemRESUMO
Schistosomiasis is on the top list of endemic diseases in sub-Saharan Africa. Praziquantel is the drug of choice for treatment of human schistosomiasis. Yet, the sole dependence on the drug raises concerns about the potential for increased drug resistance, which would subsequently result in searching for alternative preventive chemotherapy options, ideally among natural compounds. Therefore, we conducted this work to assess the effect of omega-3 polyunsaturated fatty acids [(ω-3) PUFAs] monotherapy or combined therapy with artemether (ART) against Schistosoma mansoni infection in a mouse model. A total of 42 mice were divided into 4 groups and infected with 50 ± 5 S. mansoni cercariae for 10 weeks. Mice were treated orally with either (ω-3) PUFAs as 273 mg/ kg, 4 times/ week throughout the experiment, ART as a single dose of 400 mg/ kg, 3 weeks post-infection, or combined ART + (ω-3) PUFAs using the same respective treatment regimen, while infected untreated mice were served as controls. The study explored that combined administration of (ω-3) PUFAs and ART has the best schistosomicidal efficacy as it significantly reduced liver and spleen indices, worm count, egg burdens, and granulomas count as well as diameter. Besides, the combined regimen was associated with a significant decrease in both hepatic nitric oxide and serum interleukin-4 level. The results highlighted the possibility of using (ω-3) PUFA combined with ART as a novel anti-schistosomal combination therapy. However, further researches should be conducted to clarify the possible synergistic mechanism/s between the two natural compounds.
Assuntos
Artemeter/administração & dosagem , Artemeter/farmacologia , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Ômega-3/farmacologia , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose/tratamento farmacológico , Esquistossomicidas/farmacologia , África Subsaariana , Animais , Modelos Animais de Doenças , Combinação de Medicamentos , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Schistosoma mansoni/fisiologia , Esquistossomicidas/administração & dosagemRESUMO
Background: Schistosomiasis is a major neglected disease for which the current control strategy involves mass treatment with praziquantel, the only available drug. Hence, there is an urgent need to develop new antischistosomal compounds. Methods: The antischistosomal activity of hederacolchiside A1 (HSA) were determined by total or female worm burden reductions in mice harboring Schistosoma japonicum or S. mansoni. Pathology parameters were detected on HSA against 1-day-old S. japonicum-harboring mice. Moreover, we confirmed the antischistosomal effect of HSA on newly transformed schistosomula (NTS) of S. japonicum in vitro. Results: HSA, a natural product isolated from Pulsatilla chinensis (Bunge) Regel, was initially corroborated to possess promising antischistosomal properties. We demonstrated that HSA had high activity against S. japonicum and S. mansoni less in 11 days old parasites harbored in mice. The antischistosomal effect was even more than the currently used drugs, praziquantel, and artesunate. Furthermore, HSA could ameliorate the pathology parameters in mice harboring 1-day-old juvenile S. japonicum. We also confirmed that HSA-mediated antischistosomal activity is partly due to the morphological changes in the tegument system when NTS are exposed to HSA. Conclusions: HSA may have great potential to be an antischistosomal agent for further research.
Assuntos
Pulsatilla/química , Saponinas/administração & dosagem , Esquistossomose/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Animais , Artemisininas/administração & dosagem , Artemisininas/farmacologia , Artesunato , Modelos Animais de Doenças , Feminino , Camundongos , Extratos Vegetais/química , Praziquantel/administração & dosagem , Praziquantel/farmacologia , Saponinas/química , Saponinas/farmacologia , Schistosoma japonicum/efeitos dos fármacos , Schistosoma mansoni/efeitos dos fármacos , Esquistossomicidas/química , Esquistossomicidas/farmacologiaRESUMO
BACKGROUND: The development of new treatments against schistosomiasis is imperative but lacks commercial interest. Drug repurposing represents a suitable strategy to identify potential treatments, which have already unblocked several essential steps along the drug development path, hence reducing costs and timelines. Promoting this approach, the Medicines for Malaria Venture (MMV) recently distributed a drug repurposing library of 400 advanced lead candidates (Stasis Box). METHODS: All 400 compounds were initially tested in vitro against the larval stage of Schistosoma mansoni at 10 µM. Hits progressed to screening on adult worms and were further characterised for IC50, cytotoxicity and selectivity. Ten lead compounds were tested in mice harbouring a chronic S. mansoni infection. RESULTS: Eleven of the 37 compounds active on the larval stage were also highly active on adult worms in vitro (IC50 = 2.0-7.5 µM). IC50 values on adult S. mansoni decreased substantially in the presence of albumin (7.5-123.5 µM). Toxicity to L6 and MRC cells was moderate. A moderate worm burden reduction of 51.6% was observed for MMV690534, while the other 9 compounds showed low activity. None of the in vivo results were statistically significant (P > 0.05). CONCLUSIONS: Phenotypic screening of advanced lead compounds is a simple and resource-low method to identify novel anthelminthics. None of the promising hits of the Stasis Box identified in vitro against S. mansoni yielded acceptable worm burden reductions in vivo, which might be due to the high plasma protein binding. Since the in vitro hits interfere with different drug targets, they might provide a starting point for target based screening and structure-activity relationship studies.
Assuntos
Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos , Reposicionamento de Medicamentos/métodos , Schistosoma mansoni/efeitos dos fármacos , Esquistossomicidas/farmacologia , Esquistossomicidas/uso terapêutico , Animais , Antimaláricos/química , Antimaláricos/farmacologia , Concentração Inibidora 50 , Larva/efeitos dos fármacos , Camundongos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomose mansoni/parasitologia , Esquistossomose mansoni/prevenção & controle , Esquistossomicidas/administração & dosagem , Esquistossomicidas/toxicidade , Relação Estrutura-AtividadeRESUMO
Schistosoma mansoni is one of the parasites causing schistosomiasis, a disease which threatens millions of people all over the world. Traditional chemical drugs are not fully effective against schistosomaisis due to the evolving drug resistant worm strains, so exploring new remedies derived from natural products is a good way to fight schistosomiasis. In the present investigation two natural products, Nigella sativa oil and Chroococcus turgidus extract were used separately or in a combination to explore their effect on S. mansoni. The infected mice treated with Chroococcus turgidus extract or/and sativa seed oil showed a significant decrease in the total worm burden. The total number of deposited eggs by females of S. mansoni was significantly decreased in the liver of mice treated with Chroococcus turgidus extract or/and sativa seed oil. However, in the intestine, the number of eggs was significantly reduced in mice treated with algal extract and those treated with both algal extract and oil. Fecundity of female S. mansoni showed a significant decrease from mice treated with algal extract or/and sativa seed oil. According to SEM investigations the tegmental surface, oral and ventral suckers of worms also showed considerable changes; as the tubercles lost their spines, some are swollen and torn out. The suckers become edematous and enlarged while the tegmental surface is damaged due to the treatment with Chroococcus turgidus extract or/and sativa seed oil. In conclusion, the Nigella sativa oil and Chroococcus turgidus extract are promising natural compounds that can be used in fighting schistosomiasis.
Assuntos
Cianobactérias/química , Intestinos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Extratos Vegetais/administração & dosagem , Óleos de Plantas/administração & dosagem , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Administração Oral , Animais , Modelos Animais de Doenças , Feminino , Intestinos/parasitologia , Fígado/parasitologia , Masculino , Camundongos , Microscopia Eletrônica de Varredura , Contagem de Ovos de Parasitas , Fitoterapia , Extratos Vegetais/isolamento & purificação , Plantas Medicinais , Schistosoma mansoni/ultraestrutura , Esquistossomose mansoni/parasitologia , Esquistossomicidas/isolamento & purificaçãoRESUMO
In 2008 in Morogoro region, Tanzania, mass drug administration (MDA) to school-aged children to treat two neglected tropical diseases (NTDs) - urinary schistosomiasis and soil-transmitted helminths - was suspended by the Ministry of Health and Social Welfare after riots broke out in schools where drugs were being administered. This article discusses why this biomedical intervention was so vehemently rejected, including an eyewitness account. As the protest spread to the village where I was conducting fieldwork, villagers accused me of bringing medicine into the village with which to 'poison' the children and it was necessary for me to leave immediately under the protection of the Tanzanian police. The article examines the considerable differences between biomedical and local understandings of one of these diseases, urinary schistosomiasis. Such a disjuncture was fuelled further by the apparent rapidity of rolling out MDA and subsequent failures in communication between programme staff and local people. Rumours of child fatalities as well as children's fainting episodes and illnesses following treatment brought about considerable conjecture both locally and nationally that the drugs had been either faulty, counterfeit, hitherto untested on humans or part of a covert sterilization campaign. The compelling arguments by advocates of MDA for the treatment of NTDs rest on the assumption that people suffering from these diseases will be willing to swallow the medicine. However, as this article documents, this is not always the case. For treatment of NTDs to be successful it is not enough for programmes to focus on economic and biomedical aspects of treatment, rolling out 'one size fits all' programmes in resource-poor settings. It is imperative to develop a biosocial approach: to consider the local social, biological, historical, economic and political contexts in which these programmes are taking place and in which the intended recipients of treatment live their lives. If this is not done, the world's poor will continue to be neglected.
Assuntos
Controle de Doenças Transmissíveis , Comunicação , Tumultos , Esquistossomose/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Recusa do Paciente ao Tratamento , Adulto , Anti-Helmínticos/administração & dosagem , Criança , Feminino , Helmintíase/tratamento farmacológico , Helmintíase/epidemiologia , Helmintíase/transmissão , Humanos , Masculino , Esquistossomose/epidemiologia , Esquistossomose/transmissão , Solo/parasitologia , Estudantes , Tanzânia/epidemiologia , Comportamento VerbalRESUMO
BACKGROUND: The intensive use of Praziquantel for the treatment of schistosomiasis has raised concerns about the possible emergence of drug-resistant schistosomes. As drug treatment is an important feature of schistosome control programs, the search for alternative drugs is therefore a priority. The aim of this study was to assess the schistosomicidal, hepatoprotective and antioxidant activities of the methanolic fraction from Clerodendrum umbellatum Poir leaves aqueous extract. METHODS: A phytochemical screening of the fraction of C. umbellatum was conducted. The fraction was administered orally and daily to Schistosoma mansoni-infected mice (BALB/c) from the 36th day post-infection for 28 days at 100, 200 and 400 mg/kg. Praziquantel (500 mg/kg) was used as reference drug. Non-infected and infected-untreated mice served as controls. All mice were sacrificed at 65th day post-infection. Body weight, liver/body and spleen/body weights, as well as worm burden, fecal egg count, liver and intestine egg load were determined. In the plasma, levels of total protein, transaminases (ALT, AST), alkaline phosphatase and total bilirubin were monitored to assess the possibility of liver damage. Malondialdehyde (MDA), catalase (CAT) and glutathione (GSH) levels were measured in the liver as biomarkers of the oxidative stress. RESULTS: The phytochemical analysis of the fraction from C. umbellatum aqueous leaves extract revealed the presence of alkaloids, flavonoids, cardiac glycosides, phenols, saponins, tannins and terpenoids. The worm burden, fecal egg count and egg load in the liver and intestine of infected mice treated with the fraction were significantly (p < 0.001) fewer than in infected-untreated mice. Only the highest-fraction dose reduced the worm and egg burdens in a similar way as praziquantel. Hepatosplenomegaly induced by S. mansoni infection was reduced by the treatment. The liver function on infected mice was ameliorate after administration of the fraction by significant reduction of ALT activity (35.43 to 45.25%) and increase of total protein level (44.79 to 70.03%). The methanolic fraction of C. umbellatum prevents the elevated MDA level induced by the infection while significant increase in catalase activity (297.09 to 438.98%) and glutathione level (58.23 to 95.88%) were observed after treatment. CONCLUSIONS: This study disclosed the schistosomicidal, hepatoprotective and antioxidant activities of the methanolic fraction from C. umbellatum leaves aqueous. These fraction's activities were similar to those of praziquantel. This fraction can be considered as a promising source for schistosomicidal agents.
Assuntos
Antioxidantes/administração & dosagem , Clerodendrum/química , Extratos Vegetais/administração & dosagem , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Animais , Feminino , Humanos , Fígado/efeitos dos fármacos , Fígado/parasitologia , Fígado/fisiopatologia , Testes de Função Hepática , Camundongos , Camundongos Endogâmicos BALB C , Folhas de Planta/química , Schistosoma mansoni/fisiologia , Esquistossomose mansoni/parasitologia , Esquistossomose mansoni/fisiopatologiaRESUMO
OBJECTIVE: To observe the toxicity of fangyouling after one month' s transdermal administration in rabbits and evaluate its security. METHODS: Forty rabbits were randomly divided into 4 groups including a control group and low, middle and high dose groups of fangyouling. The rabbits in the control group were administered with sunflower oil, and the other rabbits were administrated dermally with fangyouling of 50,300 and 2,000 mg/kg respectively once a day for 4 weeks. The general condition, the skin irritation reaction, body weight, food consumption, hematology, blood biochemistry, organ coefficients and histopathological changes of all the rabbits were observed. RESULTS: There was no obvious effect on the general condition in all the rabbits. However, the mild skin irritation was observed in 2 rabbits of the middle dose group and 4 rabbits of the high-dose group. The decreases of body weight and food consumption were noted in the high dose group. No changes were detected of hematology, blood biochemistry or viscera pathological at all dose levels. CONCLUSION: The dose of non-toxic response of fangyouling is 50 mg/kg at this study condition.
Assuntos
Medicamentos de Ervas Chinesas/toxicidade , Esquistossomicidas/toxicidade , Administração Cutânea , Estruturas Animais/efeitos dos fármacos , Animais , Peso Corporal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Medicamentos de Ervas Chinesas/administração & dosagem , Feminino , Humanos , Masculino , Modelos Animais , Coelhos , Esquistossomose/sangue , Esquistossomose/tratamento farmacológico , Esquistossomose/fisiopatologia , Esquistossomicidas/administração & dosagem , Testes de Toxicidade CrônicaRESUMO
The parasite Schistosoma mansoni (Sm) depends exclusively on the salvage pathway for its purine requirements. The enzyme purine nucleoside phosphorylase (PNP) is, therefore, a promising target for development of antischistosomal agents and an assay for screening of inhibitors. To enable this, immobilized SmPNP reactors were produced. By quantification of hypoxanthine by liquid chromatography, kinetic constants (K M) for the substrate inosine were determined for the free and immobilized enzyme as 110 ± 6.90 µmol L (-1) and 164 ± 13.4 µmol L (-1), respectively, indicating that immobilization did not affect enzyme activity. Furthermore, the enzyme retained 25 % of its activity after four months. Non-Michaelis kinetics for the phosphate substrate, and capacity for Pi-independent hydrolysis were also demonstrated, despite the low rate of enzymatic catalysis. Use of an SmPNP immobilized enzyme reactor (IMER) for inhibitor-screening assays was demonstrated with a small library of 9-deazaguanine analogues. The method had high selectivity and specificity compared with screening by use of the free enzyme by the Kalckar method, and furnished results without the need for verification of the absence of false positives.
Assuntos
Bioensaio/instrumentação , Avaliação Pré-Clínica de Medicamentos/instrumentação , Purina-Núcleosídeo Fosforilase/antagonistas & inibidores , Purina-Núcleosídeo Fosforilase/química , Schistosoma mansoni/enzimologia , Esquistossomicidas/química , Espectrofotometria Ultravioleta/instrumentação , Adsorção , Animais , Desenho de Fármacos , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/análise , Inibidores Enzimáticos/química , Enzimas Imobilizadas/química , Desenho de Equipamento , Análise de Falha de Equipamento , Purina-Núcleosídeo Fosforilase/análise , Reprodutibilidade dos Testes , Esquistossomicidas/administração & dosagem , Esquistossomicidas/análise , Sensibilidade e EspecificidadeRESUMO
CONTEXT: The cryptolepines originate from the roots of the climbing shrub Cryptolepis sanguinolenta (Lindi) Schitr(Periplocaeae) which is used in Central and West Africa in traditional medicine for the treatment of malaria. OBJECTIVES: Evaluation for the first time of a series of chloro- and aminoalkylamino derivatives of neo- and norneocryptolepines for potential schistosomicidal and molluscicidal activities. MATERIALS AND METHODS: A series of chloro- and aminoalkylamino substituted neo- and norneocryptolepine derivatives were synthesized. They were tested in vitro against viable Schistosoma mansoni Sambon mature worms in culturemedium with fetal serum and antibiotics and in dechlorinated water against the snail vector Biomphalaria alexandrina Ehrenberg. Active compounds were further subjected to determination of their IC50 values. RESULTS: Results showed that six neocryptolepine and two norneocryptolepine derivatives had in vitro schistosomicidal activity on Egyptian and Puerto Rican strains of S. mansoni. The most effective derivative (2-chloro-5-methyl-N-(2-morpholin-4-ethyl)-5H-indolo[2,3b]quinoline-11-amine) has IC50 and IC90 1.26 and 4.05 µM and 3.54 and 6.83 µM with the Egyptian and Puerto Rican strains of Schistosoma, respectively. All eight derivatives showed molluscicidal activity against the vector snail B. alexandrina. The most active compound (2-chloro-11-(4-methylpiperazin-1-yl)-6H-indolo[2,3-b] quinoline) has LC50 0.6 and LC90 3.9 ppm after 24 h. DISCUSSION AND CONCLUSIONS: The findings demonstrate that introducing chloro- and aminoalkylamino side chain initiated both schistosomicidal and molluscicidal activities in these derivatives. The structureactivity relationship of this series of compounds is discussed.
Assuntos
Alcaloides/farmacologia , Moluscocidas/farmacologia , Quinolinas/farmacologia , Esquistossomicidas/farmacologia , Alcaloides/administração & dosagem , Alcaloides/síntese química , Animais , Biomphalaria/efeitos dos fármacos , Cryptolepis/química , Egito , Concentração Inibidora 50 , Dose Letal Mediana , Medicinas Tradicionais Africanas , Moluscocidas/administração & dosagem , Moluscocidas/síntese química , Porto Rico , Quinolinas/administração & dosagem , Quinolinas/síntese química , Schistosoma mansoni/efeitos dos fármacos , Esquistossomicidas/administração & dosagem , Esquistossomicidas/síntese química , Relação Estrutura-Atividade , Fatores de TempoRESUMO
We have recently shown that in vitro and in vivo exposure of Schistosoma mansoni and Schistosoma haematobium to 5-10mM arachidonic acid (ARA) induces parasite surface membrane disintegration and eventual attrition. Here we report on the optimum ARA dose and post-infection treatment time for maximum schistosome demise in hamsters. A series of four experiments for each schistosome species indicated that oral administration of ARA after patency led to a highly significant (P<0.02 to <0.001) reduction in worm burden accompanied by a significant (P<0.05) decrease in worm egg load. ARA-mediated attrition in vivo appeared to be associated with high titres of serum antibodies to tegumental antigens. In support, serum antibodies from patently infected and ARA-treated hamsters readily bound to the surface membrane of ARA-exposed adult worms, as judged by indirect membrane immunofluorescence. More importantly, addition of serum antibodies and peripheral blood mononuclear cells significantly enhanced ARA-mediated adult worm attrition in vitro. These data together show that the schistosomicidal effect of ARA in laboratory animals is enhanced by immune effectors and is highly efficacious and entirely safe.
Assuntos
Ácido Araquidônico/farmacologia , Schistosoma haematobium/patogenicidade , Schistosoma mansoni/patogenicidade , Esquistossomose/tratamento farmacológico , Esquistossomicidas/farmacologia , Animais , Antígenos de Helmintos/metabolismo , Ácido Araquidônico/administração & dosagem , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Cricetinae , Avaliação Pré-Clínica de Medicamentos , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Leucócitos Mononucleares/metabolismo , Fígado/parasitologia , Fígado/patologia , Masculino , Mesocricetus , Microscopia Eletrônica de Varredura , Contagem de Ovos de Parasitas , Schistosoma haematobium/efeitos dos fármacos , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose/parasitologia , Esquistossomicidas/administração & dosagem , Fatores de TempoRESUMO
OBJECTIVE: To evaluate the preventive effect of Fangyouling (a plant cercaricide) for schistosome infection in the field. METHODS: Villagers contacting schistosome infested water in 3 administrative villages in Hubei Province were randomly selected, and the villagers rubbing Fangyouling before they contacted with the infested water were divided into Group I (159 cases) and those not rubbing Fangyouling before they contacted with the infested water were divided into Group II (172 persons). All the villagers were investigated by questionnaire, and their infections of schistosome were tested by sera and fecal examinations. RESULTS: There were no differences of constituent ratios of gender, age, occupation, time and type of infested water contact between the two groups (all P values > 0.05). The positive rates of sera and fecal examinations were 3.14% and 1.87%, respectively in Group I , and the positive rates of sera and fecal examinations were 9.30% and 6.40%, respectively in Group II, and there were significant differences between both the results of sera and fecal examinations of Group I and Group II (both P values < 0.05). In Group I , there were 110 people who completely embrocated Fangyouling, and their positive rates of sera and fecal examinations were 0.91% and 0, respectively. There are 42 people who incompletely embrocated Fangyouling, and their positive rates of sera and fecal examinations were 8.16% and 6.12%, respectively, and there were significant differences (both P values < 0.05). CONCLUSIONS: The preventive effect of schistosome infection of Fangyouling is significant. Incomplete embrocating may be one of the possible reasons for people still being infected with schistosome after rubbing the protective agent.
Assuntos
Extratos Vegetais/administração & dosagem , Substâncias Protetoras/administração & dosagem , Schistosoma/efeitos dos fármacos , Esquistossomose/prevenção & controle , Esquistossomicidas/administração & dosagem , Administração Tópica , Adulto , Idoso , Animais , Bovinos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Schistosoma/isolamento & purificação , Schistosoma/fisiologia , Esquistossomose/tratamento farmacológico , Esquistossomose/parasitologia , Adulto JovemRESUMO
Both the urinary and intestinal forms of schistosomiasis are thought to be widespread in the Republic of Yemen, with estimates of 3 million people infected and 600 000 suffering clinical morbidity. Sub-national control has been ongoing since 2006 via the distribution of praziquantel (PZQ) against schistosomiasis and albendazole (ALB) against soil-transmitted helminths using school-based treatment. In preparation for a 6-year nationwide control programme with the aim of expanding treatment to the wider community, a new programmatic approach of complementing school-based distribution with community-based treatment was trialled in 10 highly endemic districts in three governorates in December 2009. The new approach achieved coverage of 90.1% of non-enrolled children: a 40% increase compared with the same districts in 2008, and coverage of 97.9% of enrolled children: a 2% increase compared to 2008. Coverage of females (children and adults) was 81.8%, and of adults in general was 73.9%. The total cost per person treated was US$0.66 (US$0.79 in 2008), which includes training, health education, social mobilization, distribution and drugs. These results provide hope that a combined school and community-based approach can be successfully implemented on a wider scale during the main control programme in 2010-2015, with approximately 10 million people targeted in the first year alone.
Assuntos
Albendazol/administração & dosagem , Anti-Helmínticos/administração & dosagem , Serviços de Saúde Comunitária/organização & administração , Praziquantel/administração & dosagem , Esquistossomose/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Serviços de Saúde Escolar/organização & administração , Adolescente , Criança , Serviços de Saúde Comunitária/economia , Feminino , Humanos , Masculino , Projetos Piloto , Esquistossomose/epidemiologia , Esquistossomose/prevenção & controle , Serviços de Saúde Escolar/economia , Solo/parasitologia , Iêmen/epidemiologiaRESUMO
This study aims to detect the antischistosomal properties of the plants' Chenopodium ambrosioides, Conyza dioscorides and Sesbania sesban methanol extract against Schistosoma mansoni in infected mice, including determination of total protein and albumin levels and the activities of alanine and aspartate transaminases (AlT, AsT) and acid and alkaline phosphatases (AcP and AkP) enzymes in the serum of infected treated mice. Male Swiss albino mice were infected with S. mansoni and orally treated with methanol extract of the plants C. ambrosioides (1250 mg/kg/day), C. dioscorides and S. sesban (1000 mg/kg/day from each) for 2 consecutive days 7 weeks post infection (PI). In addition, treatment of mice with the tested dose of each plant extract was successively done (i.e. the 1st extract followed by the 2nd and 3rd one with an hour interval). Parasitological and biochemical parameters were assessed. Nine weeks PI, the reduction rates of worm load/mouse treated with either C. dioscorides (1000 mg/kg), C. ambrosioides (1250 mg/kg) or S. sesban (1000 mg/kg) were 40.9%, 53.7% and 54.4%, respectively. Successive treatment raised the reduction rates of worm load/mouse to 66.3% and the ova/g tissue in liver to 76.9%. Moreover, serum total protein and albumin levels and activities of AlT, Ast, AcP and AkP enzymes of infected treated mice were improved in comparison with those of infected untreated ones. It is concluded that administration of C. dioscorides, C. ambrosioides and S. sesban methanol extract to infected mice exhibited a moderate antischistosomal effect. Successive treatment improved the antischistosomal properties of these plant species, hence ameliorated the liver functions of treated mice that may suggest degenerations of liver granulomas and regenerative changes.
Assuntos
Intestinos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fitoterapia/métodos , Extratos Vegetais/administração & dosagem , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Administração Oral , Animais , Chenopodium ambrosioides/química , Conyza/química , Intestinos/parasitologia , Fígado/enzimologia , Fígado/parasitologia , Masculino , Metanol/química , Camundongos , Contagem de Ovos de Parasitas , Monoéster Fosfórico Hidrolases/sangue , Extratos Vegetais/química , Extratos Vegetais/uso terapêutico , Schistosoma mansoni/fisiologia , Esquistossomose mansoni/sangue , Esquistossomose mansoni/enzimologia , Esquistossomose mansoni/parasitologia , Esquistossomicidas/química , Esquistossomicidas/uso terapêutico , Albumina Sérica/análise , Sesbania/química , Transaminases/sangueAssuntos
Artemisininas/uso terapêutico , Schistosoma japonicum/efeitos dos fármacos , Esquistossomose Japônica/tratamento farmacológico , Esquistossomicidas/uso terapêutico , Animais , Artemisininas/administração & dosagem , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Feminino , Camundongos , Schistosoma japonicum/isolamento & purificação , Esquistossomose Japônica/parasitologia , Esquistossomicidas/administração & dosagemRESUMO
The immunostimulatory effects of methanolic extract from Pulicaria crispa were investigated in mice before and after infection with Schistosoma mansoni. Mice were subjected for daily intra-peritoneal injection by the extract (33 ng/mouse) for 10 successive days followed by infecting every mouse with 100 S. mansoni cercariae. Treatment with the extract induced significant increase (p < 0.05) in sera-IL-2 before and after infection. Upon using soluble worm antigen preparation or cancer bladder homogenates as antigens in ELISA, the detected levels of IgG were significantly (p < 0.05) higher in sera from treated-infected mice than untreated P. crispa infected mice. Using crude Escherichia coli lysate as an antigen in ELISA, it was detected a significant (p < 0.05) increase in IgG levels in sera from the extract-treated mice before and after infection.
Assuntos
Adjuvantes Imunológicos/farmacologia , Extratos Vegetais/farmacologia , Pulicaria , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/farmacologia , Adjuvantes Imunológicos/administração & dosagem , Animais , Anticorpos Antiprotozoários/sangue , Modelos Animais de Doenças , Ensaio de Imunoadsorção Enzimática , Escherichia coli/imunologia , Feminino , Humanos , Imunoglobulina G/sangue , Injeções Intraperitoneais , Interleucina-2/sangue , Camundongos , Componentes Aéreos da Planta , Extratos Vegetais/administração & dosagem , Schistosoma mansoni/imunologia , Esquistossomose mansoni/imunologia , Esquistossomose mansoni/parasitologia , Esquistossomicidas/administração & dosagem , Fatores de Tempo , Regulação para Cima , Neoplasias da Bexiga Urinária/imunologiaRESUMO
A primary objective of schistosomiasis control programmes is to achieve, and hence also demonstrate, a quantifiable reduction in schistosome-associated morbidity as a consequence of chemotherapeutic intervention. Inherent within such an objective, it is necessary to define and validate direct and indirect indicators of schistosome-related morbidity. However, to define and thereby document such morbidity, and its reduction following treatment, may not be straightforward, particularly for intestinal schistosomiasis-induced morbidity, which is often not apparent in all but the most severe or chronic cases. Within all 'Schistosomiasis Control Initiative' activities, across selected sub-Saharan African countries since 2002, a range of standard and novel potential morbidity markers have been monitored and evaluated. Parasitological intensity measures, combined with haemoglobin/anaemia counts and ultrasonography, proved valuable schistosomiasis-related morbidity indicators, being both logistically practical and informative. Additional measures tested, such as albumin excretion profiles, were promising, and are subject to ongoing research, whilst some measures, such as distended stomach/umbilical circumference, anthropometrics and health questionnaires proved less reliable. These results serve to both illustrate the success of current control activities in reducing schistosome-induced morbidity, and to highlight key tools and techniques for continued application within ongoing and future mass drug administration programmes.
Assuntos
Esquistossomose/diagnóstico , Esquistossomose/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Esquistossomicidas/uso terapêutico , África Subsaariana/epidemiologia , Antropometria , Biomarcadores , Hemoglobinúria , Humanos , Programas Nacionais de Saúde/organização & administração , Esquistossomose/epidemiologia , Esquistossomose/urina , Inquéritos e Questionários , Circunferência da CinturaRESUMO
BACKGROUND: The treatment and control of schistosomiasis, an often neglected tropical disease that exacerbates poverty, depends on a single drug, praziquantel. The large-scale use of praziquantel might select for drug-resistant parasites, hence there is a need to develop new antischistosomal compounds. Here, we report that the antimalarial drug mefloquine possesses promising antischistosomal properties in mice. METHODOLOGY/PRINCIPAL FINDINGS: A single dose of mefloquine (200 or 400 mg/kg) administered orally to mice infected with adult Schistosoma mansoni or adult S. japonicum resulted in high or complete total and female worm burden reductions (72.3%-100%). Importantly, high worm burden reductions were also observed for young developing stages of S. mansoni and S. japonicum harbored in the mouse. Both mefloquine erythro-enantiomers resulted in high and comparable total and female worm burden reductions when given to mice with either a sub-patent or patent S. mansoni infection. CONCLUSIONS/SIGNIFICANCE: Our findings hold promise for the development of a novel antischistosomal drug based on an aminoalcohol functionality. Further in vitro and in vivo studies have been launched to elucidate the possible mechanism of action and to study the effect of mefloquine on S. haematobium and other trematodes. It will be interesting to investigate whether mefloquine, which is widely and effectively used for the treatment of malaria, has an impact on schistosomiasis in areas where both malaria and schistosomiasis co-exist.
Assuntos
Mefloquina/farmacologia , Schistosoma japonicum/efeitos dos fármacos , Schistosoma mansoni/efeitos dos fármacos , Esquistossomicidas/farmacologia , Administração Oral , Animais , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Feminino , Masculino , Mefloquina/administração & dosagem , Mefloquina/química , Camundongos , Camundongos Endogâmicos , Esquistossomicidas/administração & dosagem , Esquistossomicidas/químicaRESUMO
Control programmes generally use a school-based strategy of mass drug administration to reduce morbidity of schistosomiasis and soil-transmitted helminthiasis (STH) in school-aged populations. The success of school-based programmes depends on treatment coverage. The community-directed treatment (ComDT) approach has been implemented in the control of onchocerciasis and lymphatic filariasis in Africa and improves treatment coverage. This study compared the treatment coverage between the ComDT approach and the school-based treatment approach, where non-enrolled school-aged children were invited for treatment, in the control of schistosomiasis and STH among enrolled and non-enrolled school-aged children. Coverage during the first treatment round among enrolled children was similar for the two approaches (ComDT: 80.3% versus school: 82.1%, P=0.072). However, for the non-enrolled children the ComDT approach achieved a significantly higher coverage than the school-based approach (80.0 versus 59.2%, P<0.001). Similar treatment coverage levels were attained at the second treatment round. Again, equal levels of treatment coverage were found between the two approaches for the enrolled school-aged children, while the ComDT approach achieved a significantly higher coverage in the non-enrolled children. The results of this study showed that the ComDT approach can obtain significantly higher treatment coverage among the non-enrolled school-aged children compared to the school-based treatment approach for the control of schistosomiasis and STH.
Assuntos
Anti-Helmínticos/uso terapêutico , Helmintíase/prevenção & controle , Programas Nacionais de Saúde/organização & administração , Esquistossomose/prevenção & controle , Esquistossomicidas/uso terapêutico , Adolescente , África/epidemiologia , Anti-Helmínticos/administração & dosagem , Criança , Serviços de Saúde Comunitária/estatística & dados numéricos , Conhecimentos, Atitudes e Prática em Saúde , Helmintíase/tratamento farmacológico , Humanos , Esquistossomose/tratamento farmacológico , Esquistossomicidas/administração & dosagem , Instituições Acadêmicas , Solo/parasitologiaRESUMO
The antischistosomal activity of clonazepam, when administered alone or in association with oxamniquine and praziquantel, was experimentally evaluated in mice infected with Schistosoma mansoni. The animals were treated 45 days post-infection with a single dose, by oral route, according to three treatment schedules: clonazepam 25 mg/kg and sacrificed 15 min, 1h or 4 h after treatment; clonazepam 1.0, 2.5 or 10.0 mg/kg and sacrificed 15 days post-treatment or with the dose of 10 mg/kg in association with oxamniquine 50 mg/kg or praziquantel 200 mg/kg, single dose, orally, every schedule with a control group. The efficacy of the drugs in vivo was assessed by means of worm counts and their distribution in mesentery and liver, mortality and oogram changes. In the chemotherapeutic schedules used, clonazepam did not present antischistosomal activity and the result of the association of this drug with oxamniquine or praziquantel was not significantly different from the one obtained when these two last drugs were administered alone. In the in vitro experiments, the worms exposed to 0.6 mg/mL clonazepam remained motionless throughout the 8-day-period of observation, without egg-laying, whereas the worms of the control group showed normal movements, egg-laying and hatching of miracidia on the last day of observation. The results obtained in the present study confirm the action of clonazepam on S. mansoni adult worm, in vitro, causing total paralysis of males and females. However, no additive or synergistic effects were observed when clonazepam were used in association with oxamniquine or praziquantel.